Wednesday, February 10, 2010, 12:39PM AEST - The Australian Stockmarket closes in 3 hours and 26 minutes.
To create a watchlist or portfolio of shares, Register

Nektar Therapeutics (NKTR)

8:00AM AEST: 11.71 USD  Up 0.31 (2.72%)  
 MORE ON NKTR 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Nektar Therapeutics (NasdaqNM:NKTR) Delayed quote dataEdit
Last Trade:11.71 USD
Trade Time: 8:00AM AEST
Change:Up 0.31 (2.72%)
Prev Close:11.40
Open:11.53
Bid:10.83 x 100
Ask:12.16 x 100
1y Target Est:12.56
Day's Range:11.40 - 11.76
52wk Range:4.00 - 12.28
Volume:611,817
Avg Vol (3m):726,540
Market Cap:1.09B
P/E (ttm):N/A
EPS (ttm):-0.20
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add NKTR to Portfolio   Download Data

 HEADLINES 
Biotech ETFs Immune To Broad Selling
Investor's Business Daily (Tue 9:34AM)
NEKTAR THERAPEUTICS Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
EDGAR Online (Fri, Feb 5)
NEKTAR THERAPEUTICS Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financia
EDGAR Online (Wed, Feb 3)
Nektar appoints Greer to board
AP (Wed, Feb 3)
Nektar adds to board of directors
at bizjournals.com (Wed, Feb 3)
Nektar Therapeutics Appoints R. Scott Greer to Board of Directors
PR Newswire (Wed, Feb 3)
Symantec adds former Intuit CEO to board
at bizjournals.com (Tue, Feb 2)
3 Stocks Ready to Roar
at Motley Fool (Wed, Jan 27)
Wall Street's Buy List
at Motley Fool (Wed, Jan 27)
Earnings Surprises For Diagnostics Companies Creates Good Stock Price Entry Point For New Investors According To Industry Expert
Wall Street Transcript (Tue, Jan 26)
More Headlines for NKTR...

 ANALYST 
EPS Est (next year) (Dec-09) :-0.96
EPS Est (in 2 years) (Dec-10) :-0.36
Avg Rec (current)*:1.6
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices